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A study by Figueiredo et al. (2013) in this issue of Immunity demonstrates that administration of anthracy-
clines induces autophagy in vivo and has a powerful protective effect in a mouse model of sepsis.Septic shock remains one of the most
formidable problems in critical-care
medicine (Rittirsch et al., 2008). It is typi-
cally caused by bacteremia and the
ensuing systemic inflammatory response
to infection. Some patients can gradually
recover and survive the ordeal. Sadly,
many reach a tipping point whereupon
they sink into an ultimately lethal down-
ward spiral of cascading failures of multi-
ple tissues and organs. An early aggres-
sive antibiotic treatment to control the
infection is essential but often insufficient
to prevent a lethal outcome. The mortal-
ity rate depends on the timing of antibi-
otic administration, but other than that,
it is not entirely clear why some patients
manage to recover while others get tip-
ped over the edge and quickly become
impossible to save. Needless to say,
the puzzle of septic shock has haunted
clinicians and basic scientists for de-
cades as efficient therapies for this
deadly condition have remained unavai-
lable (Iskander et al., 2013). A study by
Moita and colleagues in this issue of
Immunity describes an unexpected and
powerful therapeutic effect of anthracy-clines in a mouse model of polymicrobial
sepsis.
In this study, Figueiredo et al. used a
chemical screen to identify compounds
with anti-inflammatory properties. Among
the inhibitors they identified are epiru-
bicin, doxorubicin, and daunorubicin,
the anthracycline family drugs used
for chemotherapy of several cancers.
Anthracyclines cause DNA damage by
intercalating between base pairs and by
inhibiting topoisomerase II, the enzyme
involved in relaxing supercoiled DNA
(Minotti et al., 2004). These effects result
in inhibition of DNA replication, cell-cycle
arrest, and apoptosis of proliferating cells.
Figueiredo et al. used a cecal ligation and
puncture (CLP) model of sepsis to test the
effect of anthracyclines on bacteremia
and sepsis progression. Surprisingly,
they found that anthracycline adminis-
tration at the time of the CLP procedure
dramatically improved the survival of
mice without affecting bacterial burden.
This indicated that anthracyclines pro-
moted organ protection from sepsis, a
conclusion supported by the reduction
of several markers of organ damagein anthracycline - treated mice. As ex-
pected, administration of a broad spec-
trum antibiotic (meropenem) resulted in
a strong reduction of bacterial burden,
but although this delayed CLP-induced
mortality, it did not prevent it. Impor-
tantly, both epirubicin (anthracycline)
and meropenem (antibiotic) administra-
tion suppressed production of inflamma-
tory cytokines, including interleukin-1,
tumor necrosis factor, and high-mobility
group box 1. This indicated that reduced
cytokine production observed in epirubi-
cin-treated mice is not sufficient to
prevent mortality, suggesting that the
effects of anthracyclines cannot be
entirely explained by their anti-inflamma-
tory properties and that they might work
by promoting tissue protection from in-
flammatory damage.
These findings illustrate the distinct
contribution of tissue protection in host
defense against infection. Resistance
and tolerance are two strategies the host
canuse to survivean infection—the former
reduces pathogen burden, and the latter
minimizesdamage causedby agiven level




Autophagy Protects from Septic Shock
Multiple-tissue failure during septic shock is
caused by systemic inflammation. However,
blocking inflammation once septic shock is diag-
nosed is inefficient for preventing mortality. Activa-
tion of autophagy by the DNA-damage response
pathway in the lung has a powerful protective
effect in a mouse model of sepsis. Whether other
stimuli of autophagy activation are equally effica-
cious is not yet known.
Immunity
Previewspathogens (Ayres and Schneider, 2012;
Medzhitov et al., 2012). When immunopa-
thology or excessive inflammation are the
main causes of morbidity and mortality,
similar strategies operate by either sup-
pressing the magnitude of the inflamma-
tory response or reducing its negative
impact on host tissues.
Whereas the distinct roles of resistance
and tolerance are now increasingly well
appreciated, the molecular mechanisms
involved remain largely unknown. Using
a short hairpin RNA (shRNA)-based
screen, Figueiredo et al. identified three
kinases involved in the DNA-damage
response—the ATM (ataxia telangiectasia
mutated), ATR (ataxia telangiectasia and
Rad3 related), and CHEK1 (checkpoint
kinase 1)—as mediators of the anti-
inflammatory effects of anthracyclines
in vitro. The authors next demonstrated
that ATM is required in vivo for the protec-
tive effect of epirubicin in CLP-induced
septic shock. Remarkably, activation of
the DNA-damage response by sublethal
g irradiation was also sufficient to provide
protection from mortality of CLP-induced
sepsis. The authors next examined down-
stream targets of ATM and found that800 Immunity 39, November 14, 2013 ª2013the autophagy pathway was required
for the protective effect of epirubicin: in
autophagy-defective Lc3b/ mice the
protection was lost. This led the authors
to question which tissues required auto-
phagy activation to provide protection
from sepsis. Using inducible deletion
of another autophagy gene, Atg7, in
different cell types, Figueiredo et al. found
that autophagy functioning specifically
in the lung tissue was required for
epirubicin-induced protection from septic
shock.
This remarkable study has several
important implications. First, the attempts
to treat sepsis by targeting inflammatory
pathways have been largely unsuccessful
(Rittirsch et al., 2008). This is in part
because by the time the septic shock is
diagnosed, inflammation has already
done a great deal of damage. Moreover,
at the advanced stages of septic shock,
when the patients become very sick,
they generally enter the phase of disease
characterized by immunosuppression
(Rittirsch et al., 2008). The study by Fig-
ueiredo et al. illustrates that targeting
the tissue tolerance to damage is a
viable and perhaps the only efficacious
therapeutic option. Similar evidence was
obtained in another recent study demon-
strating the role of tissue protection
through heme detoxification in a CLP
model of sepsis (Larsen et al., 2010). The
second implication of the study by Fig-
ueiredo et al. is that mild challenge, such
as treatment with DNA-damaging drugs
or even g irradiation, can result in lasting
protective effects that can be life saving.
This phenomenon, known as hormesis,
has been particularly well documented
with regard to defense against poisons
and other toxic compounds, but it is appli-
cable to any type of challenge (Kaiser,
2003). Indeed, the phenomenon of LPS
tolerance is a relevant example of horm-
esis—low doses of lipopolysaccharide
(LPS) afford complete protection from
septic shock (Biswas and Lopez-Collazo,
2009). It is surprising that the relevant
aspect of stress response identified by
Figueiredo et al. as protective is the
DNA-damage response and autophagy.
One question raised by this finding is
whether the DNA-damage pathway has
a special role in the protection or whether
any stimulus inducing autophagy is suffi-
cient to prevent lethal tissue damage
(Figure 1). Another key question for futureElsevier Inc.studies is exactly how autophagy pro-
motes tissue tolerance after inflammatory
damage. Finally, the third important impli-
cation of this study is that it identifies the
lung as the key target organ that required
cytoprotection for the survival of the
animals. Not all tissues and organs are
equally important for survival—some are
more vital than others. The tissues, or-
gans, and physiological processes that
have the lowest tolerance to damage
and malfunction represent the weakest
links in the body, and it is their damage
or malfunction that ultimately kills. The
weakest links are not necessarily the
ones we can easily monitor or even be
aware of—they are responsible for the
proximal causes of death that are usually
unknown. However, it is obvious that
one can obtain the strongest therapeutic
effects by targeting these potentially
‘‘rate-limiting’’ processes, such as respi-
ration, cardiovascular and renal functions,
and the function of the central nervous
system. It would be important to deter-
mine whether tissue protection in the
lung is also critical for survival in human
patients.
In conclusion, the study by Figueiredo
et al. opens up an important new chapter
in the study and treatment of septic
shock. It is likely to result in new develop-
ments and treatments for this deadly
disease.
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